IPO Timeline
Broker Results (T-2)
2020-03-19
Some brokers release in afternoon
Grey Market (T-1)
2020-03-20
Afternoon
HKEX Allotment (T-1)
2020-03-20
Evening
Registrar Allotment (T-1)
2020-03-20
Evening
Listing Day (T)
2020-03-23
First day of trading
Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 诺诚健华 |
|---|---|
| Other Market Stock Code | 688428 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 諾誠健華醫藥有限公司 - B |
|---|---|
| Stock Code | 09969 |
| Company Full Name | 諾誠健華醫藥有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事生物制藥業務，專注於研究治療癌癥及自身免疫性疾病的療法。 |
| Listing Date | 2020-03-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市昌平區中關村生命科學園生命園路8號院8號樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.innocarepharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 8.95 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 50.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,120,199,900 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 9.81 |
|---|---|
| First Day Open | HK$ 9.4 |
| First Day Change | 9.61% |
| First Day Volume | 115988000.0 |
| First Day Turnover | 1148180000.0 |
Use of Proceeds
| Use of Proceeds | 1、預期約1,046.54百萬港元（相當于所得款項凈額的50.0%）將用作為奧布替尼同時在中國及美國正在進行和計劃進行的臨床試驗、準備注冊文件及潛在的商業推出（包括銷售和營銷）提供資金； 2、預期約523.27百萬港元（相當于所得款項凈額的25.0%）將用作為我們的兩個臨床階段候選產品提供資金； 3、預期約313.96百百萬港元（相當于所得款項凈額的15.0%）將用作為我們管線中的六種IND準備階段的候選藥物的研發以及新候選藥物的研發及外部引進提供資金； 4、預期約209.31百萬港元（相當于所得款項凈額的10.0%）將用作我們的營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
Overall Coordinators (4)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
UBS Securities Hong Kong Limited CE BIN466
招商证券（香港）有限公司 CE AAI650
Joint Bookrunners (6)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
UBS Securities Hong Kong Limited CE BIN466
招商证券（香港）有限公司 CE AAI650
招银国际融资有限公司 CE AVM940
浦银国际融资有限公司 CE BFZ375
Joint Lead Managers (6)
摩根士丹利亚洲有限公司 CE AAD291
高盛（亚洲）有限责任公司 CE ACC536
UBS Securities Hong Kong Limited CE BIN466
招商证券（香港）有限公司 CE AAI650
招银国际融资有限公司 CE AVM940
浦银国际融资有限公司 CE BFZ375
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Athos Asia Event Driven Master Fund | 68,306,400 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 2 | Golden Valley Global Limited | 34,153,200 HKD | — | 1.52% | — | 6 months | 2020-09-23 |
| 3 | Hankang Biotech Fund I, L.P. | 68,297,450 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 4 | Matthews Asia Funds | 157,108,300 HKD | — | 7.01% | — | 6 months | 2020-09-23 |
| 5 | Octagon Investments Master Fund LP | 40,991,000 HKD | — | 1.83% | — | 6 months | 2020-09-23 |
| 6 | Orient Sun Rise Global Superior Choice SPC | 68,297,450 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 7 | Rock Springs Capital Master Fund LP | 68,306,400 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 8 | Tiger Pacific Master Fund LP | 102,459,600 HKD | — | 4.57% | — | 6 months | 2020-09-23 |
| 9 | Vivo Funds | 170,766,000 HKD | — | 7.62% | — | 6 months | 2020-09-23 |
| 10 | WT Investment Management | 68,297,450 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 11 | 妙城集团有限公司 | 34,153,200 HKD | — | 1.52% | — | 6 months | 2020-09-23 |
| 12 | 中国国有企业结构调整基金股份有限公司 | 239,063,450 HKD | — | 10.67% | — | 6 months | 2020-09-23 |
Directors & Management
| Chairman | 崔霽松 |
|---|---|
| Company Secretary | 練少娥 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | HHLR Fund, L.P.(11.77%);彭其前(9.15%);趙仁濱及家族成員(8.37%);Vivo Capital VIII, LLC(6.97%);TMF (Cayman) Ltd.(5.94%);崔霽松(5.85%);新加坡政府投資有限公司(5.53%) |
|---|
IPO Timeline
